Benzinga's M&A Chatter for Thursday April 9, 2015

The following are the M&A deals, rumors and chatter circulating on Wall Street for Thursday April 9, 2015: Altera Shares Selloff on Report Talks With Intel Ended; Later Rally The Rumor:
Shares of Altera Corp. ALTR fell sharply in the premarket Thursday morning, on a tweet from CNBC's David Faber, that Intel Corporation INTC had broken off talks with the San Jose, CA-based semiconductor company. Shares later rebounded, as a Raymond James note said it would not be a surprise if Intel had leaked that story "in an attempt to compel Altera to reach an agreement." The Wall Street Journal first reported on March 27, that Intel was in advanced talks to acquire Altera. Altera ended the day up 3%, closing at $43.33. LinkedIn Acquires Lynda.com for $1.2B in Cash, Stock The Deal:
LinkedIn Corporation LNKD announced Thursday, that it has entered into an agreement to acquire online learning company teaching business, lynda.com, for $1.5 billion. The deal consists of approximately 52% cash and 48% in LinkedIn shares. The transaction is expected to close during Q2 of 2015. LinkedIn shares gained 1.5% Thursday, closing at $256.14. Infinera to Acquire Transmode for ~$350M in Cash, Stock Deal The Deal:
Infinera Corporation INFN, announced Thursday, an offer to acquire Transmode for approximately $350 million in cash and stock. Under the terms of the offer, for every 10 shares of Transmode, shareholders will receive SEK 300 in cash and 4.705 Infinera shares. Transmode's Board of Directors has recommended that the company's shareholders accept the offer. The deal is expected to close in Q3 of FY 2015. Infinera shares gained more than 3% Thursday, closing at $20.07. Rosetta Genomics to Acquire PersonalizeDx for $2M Cash, 500K ROSG Shares The Deal:
Rosetta Genomics Ltd. ROSG announced Thursday, it has agreed to acquire CynoGen, Inc. dba PersonalizeDx, from Prelude Corporation, for $2 million in cash and 500,000 ordinary shares of Rosetta Genomics. The deal is expected to close within the next several weeks, contingent upon the closing of Prelude's purchase of PersonalizeDx from a third party. Rosetta Genomics shares gained almost 12% Thursday, closing at $3.30.